Cocrystal Pharma, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
This is a routine Form 10-Q filing for the period ending June 30, 2026, submitted August 13, 2026. The filing contains standard quarterly disclosures, financial statements, and XBRL data files. No specific financial metrics, transactions, counterparties, or material events are detailed in the provided filing header or document list.
Why this rating
Routine periodic SEC disclosure. No material transactions, guidance changes, or events disclosed in filing metadata. Standard quarterly compliance filing.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.